Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 353, Suchdauer: 1.08s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies

von Baraliakos, Xenofon ; Bessette, Louis ; de Vlam, Kurt ; et al.

Rheumatology and Therapy. 13(3):611-628
- Zum Volltext in PubMed Central
Merkliste

2
Gemini 2.5: Pushing the Frontier with Advanced Reasoning, Multimodality, Long Context, and Next Generation Agentic Capabilities

von Comanici, Gheorghe ; Bieber, Eric ; Schaekermann, Mike ; et al.

Schlagworte: Computation and Language; Artificial Intelligence
- View full text via Arxiv
Merkliste

3
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

von Taylor, Peter C ; Kavanaugh, Arthur ; Bessette, Louis ; et al.

RMD Open ; volume 12, issue 1, page e005867 ; ISSN 2056-5933
- View full text via BASE
Merkliste

4
Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials

von Gossec, Laure ; Balanescu, Andra ; D’Agostino, Maria Antonietta ; et al.

Arthritis Research & Therapy. 28(1)
- Zum Volltext in PubMed Central
Merkliste

5
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials

von Gordon, Kenneth B. ; Blauvelt, Andrew ; Bachelez, Hervé ; et al.

Dermatology and Therapy: Research, treatment and aesthetic interventions in dermatology. :1-16
- Zum Volltext in PubMed Central
Merkliste

6
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial

von Kristensen, Lars Erik ; Keiserman, Mauro ; Papp, Kim ; et al.

Rheumatology and Therapy. 11(3):617-632
- Zum Volltext in PubMed Central
Merkliste

7
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

von Burmester, Gerd R. ; Stigler, Jayne ; Rubbert-Roth, Andrea ; et al.

Rheumatology and Therapy. 11(3):737-753
- Zum Volltext in PubMed Central
Merkliste

8
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial

von Östör, Andrew ; Van den Bosch, Filip ; Papp, Kim ; et al.

Rheumatology and Therapy. 11(3):633-648
- Zum Volltext in PubMed Central
Merkliste

9
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis

von Rubbert-Roth, Andrea ; Kakehasi, Adriana M. ; Takeuchi, Tsutomu ; et al.

Rheumatology and Therapy. 11(1):97-112
- Zum Volltext in PubMed Central
Merkliste

10
Efficacy of Risankizumab Across GRAPPA Domains in Psoriatic Arthritis: A Pooled Analysis of Patients From the Phase 3 KEEPsAKE 1 and 2 Studies

von Coates, Laura ; Blanco, Ricardo ; Behrens, Frank ; et al.

EISSN: 2056-5933 ; RMD Open ; https://hal.science/hal-05441228 ; RMD Open, 2025, 11 (3), pp.e005522. ⟨10.1136/rmdopen-2025-005522⟩

Schlagworte: psoriatic arthritis biological therapy DMARD WHAT; psoriatic arthritis; biological therapy; DMARD WHAT; [SDV]Life Sciences [q-bio]
- View full text via BASE
Merkliste

11
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

von Coates, Laura C. ; Blanco Alonso, Ricardo ; Behrens, Frank ; et al.

RMD open, 2025, 11(3), e005522
- View full text via BASE
Merkliste

12
Real-world switching and discontinuation patterns for biologic disease-modifying antirheumatic drugs in patients with active psoriatic arthritis in Japan.

von Mitsumasa Kishimoto ; Soliman, Ahmed M. ; Nunag, Dominic ; et al.

Modern Rheumatology; May2026, Vol. 36 Issue 3, p430-438, 9p

Schlagworte: Psoriatic arthritis; Japanese people; Scientific observation; Antirheumatic agents; Termination of treatment; Therapeutics; Relative medical risk
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

13
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

von McInnes, Iain B. ; Kato, Koji ; Magrey, Marina ; et al.

Rheumatology and Therapy. 10(1):275-292
- Zum Volltext in PubMed Central
Merkliste

14
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials

von Kavanaugh, Arthur ; Mease, Philip ; Gossec, Laure ; et al.

ISSN: 2578-5745 ; ACR Open Rheumatology ; https://hal.sorbonne-universite.fr/hal-04679173 ; ACR Open Rheumatology, 2024, ⟨10.1002/acr2.11714⟩.

Schlagworte: [SDV]Life Sciences [q-bio]
- View full text via BASE
Merkliste

15
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials

von Mease, Philip ; Kavanaugh, Arthur ; Gladman, Dafna ; et al.

Rheumatology and Therapy. 9(4):1181-1191
- Zum Volltext in PubMed Central
Merkliste

16
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

von Taylor, Peter C. ; Choy, Ernest ; Baraliakos, Xenofon ; et al.

Schlagworte: Janus quinases; Inibidores de Janus Quinases; Citocinas; Abrocitinib; Baricitinib; Filgotinib; Mode of action; Peficitinib; Tofacitinib; Upadacitinib
- View full text via BASE
Merkliste

17
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

von Burmester, Gerd R. ; Winthrop, Kevin ; Blanco, Ricardo ; et al.

Rheumatology and Therapy. 9(2):521-539
- Zum Volltext in PubMed Central
Merkliste

18
Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2

von Strand, Vibeke ; Van den Bosch, Filip ; Ranza, Roberto ; et al.

Rheumatology and Therapy. 8(4):1827-1844
- Zum Volltext in PubMed Central
Merkliste

19
Major Adverse Cardiovascular Events (Mace) and Venous Thromboembolism (vte) Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

von Mysler, Eduardo ; Charles-Schoeman, Christina ; Choy, Ernest ; et al.

Schlagworte: Clinical sciences; Science & Technology; Life Sciences & Biomedicine; Rheumatology
- View full text via BASE
Merkliste

20
MACE and VTE across upadacitinib clinical trial programs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

von Charles-Schoeman, Christina ; Choy, Ernest ; McInnes, Iain B ; et al.

Schlagworte: Rheumatology and arthritis; Biomedical and clinical sciences; Health sciences; General & Internal Medicine; Life Sciences & Biomedicine; Medicine; General & Internal; Science & Technology
- View full text via BASE
Merkliste

21
MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

von Charles-Schoeman, Christina ; Choy, Ernest ; McInnes, Iain B ; et al.

Schlagworte: Clinical sciences; Rheumatology and arthritis; Cardiovascular medicine and haematology; Life Sciences & Biomedicine; Rheumatology; Science & Technology
- View full text via BASE
Merkliste

22
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

23
Predictors for Achievement of Low Disease Activity at Week 56 in Patients with Psoriatic Arthritis Who Received Upadacitinib 15 mg Once Daily: Pooled Analysis of Two Phase 3 Studies

von Nash, Peter ; Aletaha, Daniel ; Mease, Philip ; et al.

Schlagworte: Cardiovascular medicine and haematology; Clinical sciences; Public health; General & Internal Medicine; Life Sciences & Biomedicine; Medicine; General & Internal; Science & Technology
- View full text via BASE
Merkliste

24
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs

von Strand, Vibeke ; Van den Bosch, Filip ; Ranza, Roberto ; et al.

Schlagworte: Cardiovascular medicine and haematology; Clinical sciences; Science & Technology; Life Sciences & Biomedicine; Medicine; General & Internal; General & Internal Medicine
- View full text via BASE
Merkliste

25
Predictors for achievement of low disease activity at week 56 in patients with psoriatic arthritis who received upadacitinib 15 mg once daily: pooled analysis of two phase 3 studies

von Aletaha, Daniel ; Mease, Philip ; Lippe, Ralph ; et al.

Schlagworte: Rheumatology and arthritis; Science & Technology; Life Sciences & Biomedicine; Rheumatology
- View full text via BASE
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag